What establishes the diagnosis?
Glaucoma
Diagnostic overview
Glaucoma assessment only; not all eye conditions.
National Eye Institute: Public diagnostic overview
Scope of this clinical reference
- Subtype criteria, optic-nerve/visual-field assessment standards and other eye diagnoses remain open.
How is it connected to service?
The applicable direct, secondary, aggravation or presumptive route determines the service-connection evidence. Use the evidence guide to distinguish these routes.
Explore service-connection evidence →What do the rating levels describe?
A diagnosis does not automatically establish a percentage. These are the source requirements for evaluating severity; related notes and exceptions still apply.
Compare these levels with the original rating table
Find DC 6012 in the rating schedule
The highlighted row marks this code. Nearby rows provide context and can describe other conditions. Use the full schedule for applicable headings, footnotes and exceptions.
| Rating | |
|---|---|
| Localized scars, atrophy, or irregularities of the retina, unilateral or bilateral, that are centrally located and that result in an irregular, duplicated, enlarged, or diminished image | 10 |
| Alternatively, evaluate based on the General Rating Formula for Diseases of the Eye, if this would result in a higher evaluation | |
| 6012 Angle-closure glaucoma | |
| Evaluate under the General Rating Formula for Diseases of the Eye. Minimum evaluation if continuous medication is required | 10 |
| 6013 Open-angle glaucoma | |
| Evaluate under the General Rating Formula for Diseases of the Eye. Minimum evaluation if continuous medication is required | 10 |
| 6014 Malignant neoplasms of the eye, orbit, and adnexa (excluding skin): | |
| Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) that require therapy that is comparable to those used for systemic malignancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the area of the eye, or surgery more extensive than enucleation | 100 |
| Note: Continue the 100 percent rating beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating will be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination will be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, evaluate based on residuals |
What an examination for visual impairment measures
When this code calls for evaluation of visual impairment, distinguish visual acuity, field loss and eye-muscle function in the examination report. The applicable findings depend on the condition.
Read 38 CFR §4.75 ↗Related notes and evaluation rules
Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091
Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes
Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions
Evaluate under the General Rating Formula for Diseases of the Eye. Minimum evaluation if continuous medication is required | 10
Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation |
What can professional assessments clarify?
A test score alone does not establish a VA percentage or service connection.
Which evidence addresses the questions?
- The documented diagnosis and applicable diagnostic code.
- Clinical findings and functional effects addressing the applicable source criteria.
- Timing, treatment and connection-to-service evidence for the applicable claim route.
Shared library and examination references
How an independent medical review works →Sources and scope
Clinical and evidence sources
Guide source check: 2026-11-06. Rating-library snapshot: June 30, 2026. Source coverage is distinct from clinical review. This page does not diagnose, adjudicate a claim, or collect medical records.
Shared reference edition 1.2.4 · source check 2026-11-06. Coverage is stated for each framework and is distinct from clinical review. Rating-source snapshot: 2026-06-30.